RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the
efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or
with AGEN1884 (Treatment Arm 2- combination therapy) for treatment of patients with advanced
cervical cancer who relapsed or progressed after receiving first-line platinum-based
chemotherapy. The study is not intended to compare the efficacy of the 2 experimental arms.
Rather, the efficacy of each arm will be evaluated against its relevant historical controls
as appropriate.